Eisai Limited
HATFIELD, England, April 20, 2011 - Halaven(TM) (eribulin), a novel treatment for patients with
locally advanced or metastatic breast cancer who have progressed after at
least two chemotherapeutic regimens for advanced disease is launched today in
Sweden, Denmark and Finland after approval by the European Drug Agency (EU)
for the whole EU area by March 24, 2011.
HATFIELD, England, April 19, 2011 - Zebinix(R) (eslicarbazepine acetate), an add-on (adjunctive) therapy for
adults with partial-onset seizures, with or without secondary generalisation
(where the seizure extensively affects consciousness of the patients by
propagation to both sides of the brain), has recently been launched in Greece
by Arriani Pharmaceuticals, Eisai's chosen partner in Greece.
